Providers at JosephCareRX monitor patients closely during dose escalation to minimize side effects and improve adherence
The state transitioned from covering older, cheaper diabetes medications like Metformin which cost $2 million annually to GLP-1s costing $200 million per year
Insured patients whose plan covers the indication often pay far less, sometimes as little as $25
These treatments can be expensive as well, and arent always covered by insurance
After reading this article, you will understand why this company is so special thanks to its world beating drug pipeline in the obesity/diabetes care space , why the company is poised to see best in class growth and excellent execution from a talented management team , why its target market is growing significantly and presents upside with future applications of its medicines, why the company has derated so much recently and why it may be poised for a turnaround
What to expect Ozempic and Rybelsus are used for blood sugar control in patients with diabetes, and Wegovy is indicated for weight management
